(UroToday.com)Stage 3 urothelial cancer has a poor prognosis, which can be improved modestly with neoadjuvant cisplatin chemotherapy prior to radical cystectomy. However, options to improve prognosis in patients that are to receive cisplatin are lacking. The NABUCCO trial, cohort 1, involved treating stage 3 urothelial cancer patient with two doses of neoadjuvant ipilimumab (3 mg/kg) with a dose of nivolumab 1 mg/kg followed by a fourth treatment dose with nivolumab 3 mg/kg. This approach resulted in a 46% pathologic complete response rate (pCR) at the time of cystectomy, and 58% of patients had either pCR or non-invasive disease.1